Allogeneic Stem Cell Transplantation

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
Robert Chen, Phillippe Armand, Michelle A Fanale, Vincent Ribrag, Pier Luigi Zinzani, Alejandro D Ricart, Seth Thompson, Arun Balakumaran, Daniel Molin, Margaret A Shipp, Craig H Moskowitz

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P146; DOI: 10.1186/2051-1426-3-S2-P146
Integrated whole genome and transcriptome analysis identified a therapeutic minor histocompatibility antigen encoded by an alternative ITGB2 transcript
Margot J Pont, Dyantha van der Lee, Edith van der Meijden, Cornelis van Bergen, Michel Kester, Maria Honders, Martijn Vermaat, Matthias Eefting, Erik Marijt, Szymon Kielbasa, Peter-Bram 't Hoen, Frederik Falkenburg, Marieke Griffioen

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P285; DOI: 10.1186/2051-1426-3-S2-P285
Tumor-specific donor lymphocyte infusion therapy with allogeneic T cells utilizing novel retrovirus vector silencing endogenous TCR expression
Hiroaki Ikeda, Hiroaki Ueno, Ayumi Kawamura, Naoko Imai, Sachiko Okamoto, Junichi Mineno, Kazutoh Takesako, Hiroshi Shiku

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P20; DOI: 10.1186/2051-1426-2-S3-P20
Next-generation dendritic cells for immunotherapy of acute myeloid leukemia
Frauke Schnorfeil, Felix Lichtenegger, Christiane Geiger, Thomas Köhnke, Veit Bücklein, Torben Altmann, Beate Wagner, Reinhard Henschler, Iris Bigalke, Gunnar Kvalheim, Wolfgang Hiddemann, Dolores Schendel, Marion Subklewe

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P84; DOI: 10.1186/2051-1426-2-S3-P84
P55. Dendritic cell vaccination for postremission therapy in AML
FS Lichtenegger, B Beck, I Bigalke, C Geiger, W Hiddemann, R Henschler, G Kvalheim, DJ Schendel, M Subklewe

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P29; DOI: 10.1186/2051-1426-2-S2-P29
S77. Proffered paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing
S Reuther, P Krell, FR Schuster, C Grabrucker, A Liepert, T Kroell, HJ Kolb, A Borkhardt, R Buhmann, H Schmetzer

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) I15; DOI: 10.1186/2051-1426-2-S2-I15
P20. Lack of T cell exhaustion in acute myeloid leukaemia
FM Schnorfeil, FS Lichtenegger, K Emmerig, M Schlüter, R Draenert, W Hiddemann, M Subklewe

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P11; DOI: 10.1186/2051-1426-2-S2-P11
P74. A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells
MM van Loenen, R de Boer, E van Liempt, RS Hagedoorn, P Meij, I Jedema, JHF Falkenburg, MHM Heemskerk

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P48; DOI: 10.1186/2051-1426-2-S2-P48
Rapid monitoring of reconstituted Wilms' tumor suppressor gene-specific t lymphocytes after allogeneic stem cell transplantation using quantitative real time Polymerase chain reaction
Ahmad A Ab-Khader, Stefan Krause, Ernst Holler

Journal for ImmunoTherapy of Cancer Feb 2014, 2 (Suppl 1) P3; DOI: 10.1186/2051-1426-2-S1-P3

Log in using your username and password

Main menu

Log in using your username and password

You are here

Allogeneic Stem Cell Transplantation